New tricyclic compounds with pyrimido [4,5-d] pyrimidine fragment, the 7,8-dihydro-1H-pyrimido [4,5,6-de] quinazoline derivatives*

V. A. Dorokhov, * V. A. Voronkova, A. V. Komkov, and A. S. Shashkov

N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky prosp., 119991 Moscow, Russian Federation. Fax: +7 (499) 135 5328. E-mail: vador@ioc.ac.ru

A reaction of 2-diaminomethylidenedimedone with aryl isocyanates leads to the formation of the corresponding ureas, which upon the action of sodium methoxide cyclize to 4-amino-7,8-dihydroquinazoline-2,5(1H,6H)-dione derivatives. The latter react with aryl isocyanates following the similar scheme to furnish 1,6-diaryl-8,8-dimethyl-7,8-dihydro-1H-pyrimido-[4,5,6-de]quinazoline-2,5(3H,6H)-diones, new tricyclic compounds containing pyrimido-pyrimidine fragment.

Key words: 2-diaminomethylidene-5,5-dimethylcyclohexane-1,3-dione, aryl isocyanates, 4-amino-7,8-dihydroquinazoline-2,5(1*H*,6*H*)-diones, cyclization, 7,8-dihydro-1*H*-pyrimido-[4,5,6-*de*]quinazoline-2,5(3*H*,6*H*)-dione derivatives, [1,5]-hydride shift.

Pyrimido[4,5-d]pyrimidines, close in the structure to pteridines and purines, are a biologically interesting system and exhibit various kinds of pharmacological activity: bronchodilatory, ¹ antibacterial, ^{2,3} antiallergic, ⁴ antihypertensive, ⁵ as well as are inhibitors of phosphodiesterase ¹ and dihydrofolatreductase. ⁶

In continuation of our studies on the synthesis of pyrimido [4,5-d] pyrimidines, ⁷⁻¹² in the present work we report on 7,8-dihydropyrimido [4,5,6-de] quinazoline-2,5-dione derivatives, tricyclic compounds containing a pyrimidopyrimidine fragment.

One of the simple and efficient ways for the construction of the pyrimido[4,5-d]pyrimidine system is based on the conversion of dioxoketene N,N-acetals with isocyanates.^{8,11}–13 Taking into account electronic and steric effects, it seems the most convenient to use ketene aminals unsubstituted at the nitrogen atoms, like, for example, in the scheme suggested by us for the synthesis of 3,6-diaryl-5-methylpyrimido[4,5-d]pyrimidine-2,4,7(1H,3H,6H)-triones.¹²

Recently, we have shown that ketene aminals of such a type can be obtained from 1,3-cyclohexanedione and dimedone. In the present work, we consider heterocyclization involving 2-diaminomethylidene-5,5-dimethyl-cyclohexane-1,3-dione (1) and aryl isocyanates. It was found that ketene aminal 1 reacts with phenyl isocyanate 2a and 4-chlorophenyl isocyanate 2b in boiling toluene with the formation of ureas 3a,b, which do not react with excess aryl isocyanate. Compounds 3a,b upon the action

of MeONa in MeOH were converted to the 4-amino-7,8-dihydroquinazoline-2,5(1H,6H)-dione derivatives **4a**,**b** (Scheme 1). Thus, the enamine fragment is involved into the heterocyclization, as in the case of the reaction of β -oxoester diaminomethylidene derivatives. ¹²

Earlier, it has been reported on the synthesis of 2-ureidomethylidenecyclohexane-1,3-diones by a three-component reaction of 1,3-cyclohexanediones, triethyl orthoformate, and urea, however, these compounds were not used in further processes of heterocyclization.¹⁵

Bicyclic compounds **4a**,**b** are also able to react with aryl isocyanates in boiling toluene with the formation of ureas **5a**,**b** in 87—89% yields. Cyclization of the latter in the presence of MeONa in MeOH leads to 1,6-diaryl-8,8-dimethyl-7,8-dihydro-1*H*-pyrimido[4,5,6-*de*]quinazoline-2,5(3*H*,6*H*)-diones **6a**,**b**, whose yields were 80 and 65%, respectively.

The synthesized compounds **3**—**6** are well soluble in chloroform. Their structures were confirmed by the IR and ¹H NMR spectroscopic data and mass spectrometric data, whereas heterocycles **4** and **6** were additionally characterized by the ¹³C NMR spectroscopic data and ¹H/¹³C HSQC and HMBC two-dimensional NMR spectra. Thus, the mass spectra (EI) of compounds **3**, **4**, and **6** exhibit peaks of molecular ions, whereas such peaks are absent in the spectra of ureas **5**, however, there are intensive peaks of the [M – RNCO]⁺ and [RNCO]⁺ ions. The IR spectra of compounds **3**—**6** are characterized by the presence of the absorption bands of the CO, NH, and (or) NH₂ group (see Experimental). In the ¹H NMR spectra (CDCl₃) of ureas **3**, unlike in that of ketene aminal **1**, the two CH₂ groups have different chemical shifts (for example, for

^{*} Dedicated to Academician of the Russian Academy of Sciences O. M. Nefedov on the occasion of his 80th birthday.

Scheme 1

$$H_2N \rightarrow NH_2$$
 $O \rightarrow NH_2$
 $O \rightarrow NH$

 $R = Ph(a), 4-ClC_6H_4(b)$

Reagents and conditions: *i.* toluene, Δ; *ii.* MeONa, MeOH, Δ; AcOH, 20 °C.

compound 3a they are at δ 2.30 and 2.37) and for dihydroquinazolines 4 and ureas 5, the differences become more pronounced (for example, for compound 4a: δ 2.28 and 2.40, for compound 5a: δ 2.35 and 2.47). In addition, if ureas 3a,b have four broad singlets from the NH and (or) NH₂ groups, each of the compounds **4a**,**b** and **5a**,**b** have only two broad singlets (nonequivalence of the protons of the NH₂ group in dihydroquinazolines 4a,b indicates formation of a hydrogen bond between the NH₂ and CO groups). The ¹H NMR spectra (CDCl₃) of dihydropyrimidoquinazolines 6 exhibit singlets for the CH₂ group at $\delta \sim 2.2$ and for the proton H(9) at $\delta \sim 4.0$. If the ¹³C NMR spectrum (DMSO-d₆) of dihydroquinazoline 4b has a signal at δ 196.0 (C(5)), compounds 6 have the most low-field signal at δ 156.6. The ¹H/¹³C HMBC two-dimensional NMR spectra of dihydropyrimidoguinazolines 6 exhibit the correlation peaks for the protons of the CH₂ group with the C(9b), C(9), C(8), C(6a) atoms and the methyl groups, whereas the protons H(9), with the C(9a), C(9b), C(8), C(7) atoms and the methyl groups. Attention should be paid to considerable differences in the chemical shifts for the C(9a) and C(6a) atoms in the ¹³C NMR spectra $(\delta 130.7-130.9 \text{ and } 154.8-155.0, \text{ respectively}), \text{ which}$ confirms that the structures of pyrimidine rings in compounds 6 significantly differ.

Varying isocyanates in the steps of preparation of bicyclic and tricyclic systems, one can obtain dihydropyrimidoquinazolinediones with different substituents at positions N(1) and N(6) (Scheme 2). By analogy with compounds $\mathbf{5a,b}$, ureas $\mathbf{5c,d}$ were synthesized for this purpose (the yields were 86-98%), whose intramolecular cycliza-

tion upon the action of MeONa in MeOH led to the formation of isomeric compounds with the suggested structures **6c**,**d** (the yields were 67 and 80%, respectively).

The IR and mass spectral data, as well as ¹H NMR spectra (300 MHz) obtained for dihydropyrimidoquinazolinediones resemble the spectral data for similar heterocycles 6a,b with the same substituents at the N(1) and N(6) atoms. However, their ¹³C NMR spectra, as well as ¹H NMR spectra (600 MHz) in both CDCl₃ and DMSO-d₆ exhibit a double set of closely placed signals (the ¹H NMR spectra in DMSO-d₆ have two signals not only for the aromatic protons and H(9) protons, but also for the protons of the CH₂ group). Recording the ¹H NMR spectra in DMSO-d₆ at 60 °C, as well as in the presence of trifluoroacetic acid, produced no changes. These data indicate that the cyclization of both the urea 5c and the urea 5d leads to isomeric compounds 6c and 6d in virtually equal ratio. Recording the ¹H/¹H COSY, ¹H/¹³C HSQC and HMBC and ¹H/¹⁵N HMBC two-dimensional NMR spectra allowed us to assign almost all the signals for compounds 6c and 6d in the ¹H and ¹³C NMR spectra (see Experimental). Heterocycles 6c and 6d do not differ in their chromatographic lability.

It can be suggested that an equilibrium between the corresponding salts is reached upon the action of a base due to the proton transfer over the cyclohexane ring, which disappears after acidification with acetic acid. Apparently, this process can be interpreted as a [1,5]-hydride shift (see review 16).

In conclusion, when pyrimidine ring is built as a part of the bi- and tricyclic systems, 2-diaminomethylidene-

Scheme 2

4a
$$\frac{2b}{i}$$
 Me $\frac{1}{N}$ Me

Reagents and conditions: i. toluene, Δ; ii. MeONa, MeOH, Δ; iii. AcOH, 20 °C.

cyclohexane-1,3-diones can be used not only as N,N-binucleophiles (like amidines), ¹⁴ but also as functionalized enaminones.

Experimental

¹H NMR spectra were recorded on a Bruker AM-300 spectrometer (300 MHz), ¹H NMR spectra of tricyclic compounds 6, ¹³C NMR spectra, and ¹H/¹H COSY, ¹H/¹³C HSQC and HMBC, ¹H/¹⁵N HMBC two-dimensional NMR spectra were recorded on a Bruker Avance 600 spectrometer (600, 150, and 60.8 MHz for ¹H, ¹³C, and ¹⁵N, respectively). Signals for the residual protons of the deuterated solvents were used as a reference in ¹H NMR spectra (7.27 for CDCl₃ and 2.50 for DMSO-d₆) and multiplet signals of the deuterated solvents, in the ¹³C NMR spectra (39.50 for DMSO-d₆ and 77.00 for CDCl₃). Chemical shifts of ¹⁵N were measured relatively to the external standard MeNO₂ (the high-field chemical shifts are given with the negative sign). IR spectra were recorded on a Specord-M82 spectrometer, and mass spectra, on a Kratos MS-30 instrument (EI, 70 eV, temperature of the ionization chamber was 250 °C, a direct injection of compounds). We used in the syntheses aryl isocyanates purchased from Lancaster, anhydrous toluene was obtained by distillation over sodium, methanol was purified by fractional distillation. 2-Diaminomethylidene-5,5-dimethylcyclohexane-1,3-dione 1 was synthesized according to the described by us procedure. 14 Column chromatography was performed on Merck silica gel 60 (0.063–0.200 mm).

2-[Amino(*N***'-phenylureido)methylidene]-5,5-dimethylcyclo-hexane-1,3-dione (3a).** Phenyl isocyanate (0.18 mL, 1.6 mmol)

was added to ketene aminal **1** (0.2 g, 1.1 mmol) in anhydrous toluene (3 mL), and the mixture was refluxed for 8 h, cooled to 20 °C, a precipitate that formed was filtered off, washed with toluene and light petroleum, and recrystallized from MeOH to obtain urea **3a** (0.23 g, 71%), m.p. 219—220 °C. Found (%): C, 63.43; H, 6.10; N, 13.81. $C_{16}H_{19}N_{3}O_{3}$. Calculated (%): C, 63.77; H, 6.36; N, 13.94. MS, m/z (I_{rel} (%)): 301 [M]⁺ (6), 209 [M – PhNH]⁺ (24), 182 [M – PhNCO]⁺ (49), 119 [PhNCO]⁺ (70), 93 [PhNH₂]⁺ (100). IR (CHCl₃), v/cm^{-1} : 3336 (NH), 3030—2950 (NH, CH), 1708 (CO), 1644, 1532. ¹H NMR (CDCl₃), δ : 0.99 (s, 6 H, 2 Me); 2.30 (s, 2 H, CH₂); 2.37 (s, 2 H, CH₂); 7.16 (t, 1 H, p-H_{Ph}, J = 7.5 Hz); 7.35 (t, 2 H, m-H_{Ph}, J = 7.5 Hz); 7.41 (d, 2 H, o-H_{Ph}, J = 7.5 Hz); 8.32 (br.s, 1 H, NHPh); 9.67 (br.s, 1 H, NH₂); 11.43 (br.s, 1 H, NH₂); 13.89 (br.s, 1 H, NH).

2-[Amino(*N*′**-4-chlorophenylureido)methylidene]-5,5-dimethylcyclohexane-1,3-dione (3b)** was synthesized similarly to urea **3a** from ketene aminal **1** and 4-chlorophenyl isocyanate, the yield was 77%, m.p. 239—240 °C (from methanol). Found (%): C, 57.49; H, 5.02; Cl, 10.70; N, 12.48. $C_{16}H_{18}CIN_{3}O_{3}$. Calculated (%): C, 57.23; H, 5.40; Cl, 10.56; N, 12.51. MS, m/z (I_{rel} (%)): 335 [M]⁺ (3), 209 [M - ClC₆H₄NH]⁺ (100), 166 [M - ClC₆H₄NCO - Me - H]⁺ (28), 153 [ClC₆H₄NCO]⁺ (27), 127 [ClC₆H₄NH₂]⁺ (55). IR (KBr), v/cm^{-1} : 3296 (NH), 3210—2950 (NH, CH), 1700 (CO), 1636, 1528. ¹H NMR (CDCl₃), δ : 1.01 (s, δ H, 2 Me); 2.31 (s, 2 H, CH₂); 2.38 (s, 2 H, CH₂); 7.31 (d, 2 H, C₆H₄, J = 7.5 Hz); 7.40 (d, 2 H, C₆H₄, J = 7.5 Hz); 8.33 (br.s, 1 H, NH_C6H₄); 9.61 (br.s, 1 H, NH₂); 11.47 (br.s, 1 H, NH₂); 13.97 (br.s, 1 H, NH).

4-Amino-7,7-dimethyl-1-phenyl-7,8-dihydroquinazoline-2,5- (1*H***,6***H***)-dione (4a).** A solution of MeONa in MeOH (0.5 mL,

0.53 mmol) was added to urea **3a** (0.16 g, 0.53 mmol) in MeOH (5 mL), and the mixture was refluxed for 1 h, cooled to 20 °C, acidified with AcOH, the solvent was evaporated *in vacuo* to dryness. The residue was diluted with water, a precipitate was filtered off, washed with diethyl ether to obtain dihydroquinazoline **4a** (0.12 g, 80%), m.p. 286—287 °C. Found (%): C, 67.95; H, 5.67; N, 14.47. $C_{16}H_{17}N_3O_2$. Calculated (%): C, 67.83; H, 6.05; N, 14.83. MS, m/z (I_{rel} (%)): 283 [M]+ (100), 268 [M – Me]+ (44), 241 [M – I_{rel} (M)+ (23), 226 [M – Me – I_{rel} (M)+ (24), 147 [M – Me – PhNCO – 2 H]+ (42), 117 [PhNCO – 2 H]+ (33). IR (CHCl₃), v/cm^{-1} : 3480, 3320 (NH), 3010—2960 (NH, CH), 1688 (CO), 1648, 1608, 1512. ¹H NMR (CDCl₃), δ : 1.02 (s, 6 H, 2 Me); 2.28 (s, 2 H, CH₂); 2.40 (s, 2 H, CH₂); 6.45 (br.s, 1 H, NH₂); 7.18 (d, 2 H, Ph, J= 7.5 Hz); 7.52 (m, 3 H, Ph); 9.00 (br.s, 1 H, NH₂).

4-Amino-1-(4-chlorophenyl)-7,7-dimethyl-7,8-dihydroquinazoline-2,5(1H,6H)-dione (4b) was synthesized similarly to dihydroquinazoline 4a from urea 3b, the yield was 62%, m.p. 290—291 °C. Found (%): C, 60.17; H, 4.65; Cl, 11.19; N, 13.17. C₁₆H₁₆ClN₃O₂. Calculated (%): C, 60.48; H, 5.08; Cl, 11.16; N, 13.22. MS, m/z (I_{rel} (%)): 317 [M]⁺ (55), 316 [M – H]⁺ (100), $302 [M - Me]^+ (14), 127 [ClC_6H_4NH_2]^+ (17), 101 (62). IR$ $(CHCl_3)$, v/cm^{-1} : 3480, 3320 (NH), 3030—2960 (NH, CH), 1680 (CO), 1648, 1608, 1512. ¹H NMR (CDCl₃), δ: 1.05 (s, 6 H, 2 Me); 2.29 (s, 2 H, CH₂); 2.42 (s, 2 H, CH₂); 6.35 (br.s, 1 H, NH₂); 7.15 (d, 2 H, C_6H_4 , J = 8.0 Hz); 7.52 (d, 2 H, C_6H_4 , J = 8.0 Hz); 9.03 (br.s, 1 H, NH₂). ¹H NMR (DMSO-d₆), δ : 0.93 (s, 6 H, 2 Me); 2.29 (s, 2 H, CH₂); 2.36 (s, 2 H, CH₂); 7.35 (d, 2 H, $o-H_{C_6H_4}$, J=7.8 Hz); 7.59 (d, 2 H, $m-H_{C_6H_4}$, J=7.8 Hz); 8.01 (br.s, 1 H, NH₂); 8.69 (br.s, 1 H, NH₂). ¹³C NMR (DMSO-d₆), δ: 27.39 (2 Me); 31.46 (C(7)); 41.71 (C(8)); 50.19 (C(6)); 99.62 $(C(4a)); 129.48 (o-C_{C_6H_4}); 130.22 (m-C_{C_6H_4}); 133.25 (p-C_{C_6H_4});$ 136.76 (*ipso*- $C_{C_6H_4}$); 153.44 (C(4)); 163.17 (C(2)); 166.05 (C(8a)); 196.04 (C(5)). Assignment of the signals performed was based on the ¹H/¹³C HMBC two-dimensional NMR.

7,7-Dimethyl-1-phenyl-4-(N'-phenylureido)-7,8-dihydroquinazoline-2,5(1H,6H)-dione (5a). Phenyl isocyanate (0.03 mL, 0.3 mmol) was added to dihydroquinazoline 4a (0.06 g, 0.2 mmol) in anhydrous toluene (3 mL), and the mixture was refluxed for 6 h, cooled to 20 °C. A precipitate that formed was filtered off, washed with toluene, dried in vacuo, and recrystallized from MeOH to obtain urea 5a (0.07 g, 87%), m.p. > 300 °C. Found (%): C, 68.78; H, 5.47; N, 13.77. C₂₃H₂₂N₄O₃. Calculated (%): C, 68.64; H, 5.51; N, 13.92. MS, $m/z(I_{rel}(\%))$: 283 [M – PhNCO]⁺ (67), 282 $[M - PhNCO - H]^+$ (100), 268 $[M - PhNCO - Me]^+$ (12), 119 [PhNCO]⁺ (80), 93 [PhNH₂]⁺ (81). IR (CHCl₃), v/cm⁻¹: 3184 (NH), 3030—2960 (NH, CH), 1696 (CO), 1648, 1596, 1528. ¹H NMR (CDCl₃), δ: 1.04 (s, 6 H, 2 Me); 2.35 (s, 2 H, CH_2); 2.47 (s, 2 H, CH_2); 7.09 (t, 1 H, p- H_{Ph} , J = 7.5 Hz); 7.21 (d, 2 H, o-H_{Ph}, J = 7.5 Hz); 7.32 (m, 3 H, m-H_{Ph}, p-H_{Ph}); 7.59 $(m, 4 H, o-H_{Ph}, m-H_{Ph}); 11.45 (br.s, 1 H, NH); 11.85 (br.s,$ 1 H, NH).

1-(4-Chlorophenyl)-4-(*N*´-**4-chlorophenylureido**)-**7,7-dimethyl-7,8-dihydroquinazoline-2,5(1***H***,6***H***)-dione (5b) was synthesized similarly to urea 5a** from dihydroquinazoline **4b** and 4-chlorophenyl isocyanate, the yield was 89%, m.p. 290—291 °C (sublimes). Found (%): C, 58.26; H, 4.14; Cl, 15.09; N, 11.72. C₂₃H₂₀Cl₂N₄O₃. Calculated (%): C, 58.61; H, 4.28; Cl, 15.04; N, 11.89. MS, m/z ($I_{\rm rel}$ (%)): 318 [M - ClC₆H₄NCO]⁺ (42), 317 [M - ClC₆H₄NCO - H]⁺ (57), 316 [M - ClC₆H₄NCO - 2H]⁺ (100), 153 [ClC₆H₄NCO]⁺ (58). IR (KBr), v/cm⁻¹: 3150—2950

(NH, CH), 1700 (CO), 1652, 1600, 1528. ¹H NMR (CDCl₃), δ : 1.06 (s, δ H, 2 Me); 2.36 (s, 2 H, CH₂); 2.48 (s, 2 H, CH₂); 7.14 (d, 2 H, C₆H₄, J = 7.5 Hz); 7.28 (d, 2 H, C₆H₄, J = 7.5 Hz); 7.53 (d, 2 H, C₆H₄, J = 7.5 Hz); 7.58 (d, 2 H, C₆H₄, J = 7.5 Hz); 11.45 (br.s, 1 H, NH); 11.86 (br.s, 1 H, NH).

4-(N'-**4-**Chlorophenylureido)-**7**,**7-dimethyl-1-phenyl-7**,**8-dihydroquinazoline-2**,**5**(1H,6H)-dione (**5c**) was synthesized similarly to urea **5a** from dihydroquinazoline **4a** and 4-chlorophenyl isocyanate, the yield was 98%, m.p. 255–256 °C (sublimes). Found (%): C, 62.88; H, 4.75; Cl, 8.06; N, 12.69. $C_{23}H_{21}ClN_4O_3$. Calculated (%): C, 63.23; H, 4.84; Cl, 8.11; N, 12.82. MS, m/z (I_{rel} (%)): 283 [M - ClC₆H₄NCO]⁺ (85), 282 [M - ClC₆H₄NCO - H]⁺ (97), 268 [M - ClC₆H₄NCO - Me]⁺ (69), 153 [ClC₆H₄NCO]⁺ (100), 127 [ClC₆H₄NH₂]⁺ (34). IR (CHCl₃), v/cm^{-1} : 3175 (NH), 3020–2960 (NH, CH), 1700 (CO), 1652, 1604, 1528. 1 H NMR (CDCl₃), δ : 1.04 (s, 6 H, 2 Me); 2.36 (s, 2 H, CH₂); 2.47 (s, 2 H, CH₂); 7.21 (m, 2 H, Ph); 7.29 (m, 2 H, C₆H₄); 7.58 (m, 5 H, C₆H₄, Ph); 11.46 (br.s, 1 H, NH); 11.94 (br.s, 1 H, NH).

1-(4-Chlorophenyl)-7,7-dimethyl-4-(*N***'-phenylureido)-7,8-dihydroquinazoline-2,5(1***H*,6*H***)-dione (5d)** was synthesized similarly to urea **5a** from dihydroquinazoline **4b** and phenyl isocyanate, the yield was 86%, m.p. 270—271 °C (sublimes). Found (%): C, 63.07; H, 4.53; Cl, 8.16; N, 12.68. $C_{23}H_{21}ClN_4O_3$. Calculated (%): C, 63.23; H, 4.84; Cl, 8.11; N, 12.82. MS, m/z (I_{rel} (%)): 317 [M – PhNCO]+ (73), 316 [M – PhNCO – H]+ (100), 302 [M – PhNCO – Me]+ (15), 127 [ClC₆H₄NH₂]+ (22); 119 [PhNCO]+ (46). IR (CHCl₃), v/cm⁻¹: 3190 (NH), 3020—2960 (NH, CH), 1696 (CO), 1652, 1604, 1528. ¹H NMR (CDCl₃), δ: 1.04 (s, 6 H, 2 Me); 2.34 (s, 2 H, CH₂); 2.46 (s, 2 H, CH₂); 7.16 (m, 3 H, o-H_{C₆H₄}, p-H_{Ph}); 7.33 (m, 2 H, m-H_{Ph}); 7.57 (m, 4 H, m-H_{C₆H₄}, o-H_{Ph}); 11.42 (br.s, 1 H, NH); 11.80 (br.s, 1 H, NH)

8,8-Dimethyl-1,6-diphenyl-7,8-dihydro-1*H*-pyrimido[4,5,6de quinazoline-2,5(3H,6H)-dione (6a). A solution of MeONa in MeOH (0.2 mL, 0.2 mmol) was added to urea 5a (0.08 g, 0.2 mmol) in MeOH (5 mL), and the mixture was refluxed for 10 min, cooled to 20 °C, acidified with AcOH, the solvent was evaporated in vacuo to dryness. The residue was diluted with water, a precipitate was filtered off and recrystallized from the benzene—methanol mixture to obtain compound **6a** (0.06 g, 80%), m.p. 308—309 °C. Found (%): C, 71.50; H, 5.19; N, 14.30. C₂₃H₂₀N₄O₂. Calculated (%): C, 71.86; H, 5.24; N, 14.57. MS, m/z (I_{rel} (%)): 384 [M]⁺ (7), 369 [M – Me]⁺ (100), 326 $[M - 2 Me - CO]^+$ (13), 250 $[M - Me - PhNCO]^+$ (4), 119 $[PhNCO]^{+}$ (17), 93 $[PhNH_{2}]^{+}$ (73). IR (CHCl₃), v/cm^{-1} : 3392 (NH), 3024, 1712 (CO), 1652, 1632, 1560. ¹H NMR (CDCl₃), δ: 0.93 (s, 6 H, 2 Me); 2.22 (s, 2 H, CH₂); 3.99 (s, 1 H, H(9)); 7.22 (d, 2 H, o-H_{Ph}, J = 8.0 Hz); 7.28 (d, 2 H, o-H_{Ph}, J = 8.0 Hz); 7.53 (m, 6 H, m-H, 2 Ph; p-H, 2 Ph); 7.97 (br.s, 1 H, NH). ¹³C NMR (CDCl₃), δ: 28.62 (2 Me); 32.31 (C(8)); 40.16 (C(7)); 95.12 (C(9b)); 106.95 (C(9)); 127.75 (*o*-C_{Ph}); 128.88 (*o*-C_{Ph}); $128.92 (p-C_{Ph}); 129.50 (p-C_{Ph}); 129.98 (m-C_{Ph}); 130.06 (m-C_{Ph});$ 130.88 (C(9a)); 136.16 (ipso-C_{Ph}); 136.68 (ipso-C_{Ph}); 155.02 (C(6a)); 148.93, 156.02, 156.56 (C(2), C(3a), C(5)). Assignment of the signals performed was based on the ¹H/¹³C HMBC twodimensional NMR.

1,6-Di(4-chlorophenyl)-8,8-dimethyl-7,8-dihydro-1H-pyrimido[4,5,6-de]quinazoline-2,5(3H,6H)-dione (6b) was synthesized similarly to compound 6a from urea 5b, the yield was 65%, m.p. 295—296 °C (from the benzene—methanol mixture). Found (%):

C, 60.92; H, 4.27; Cl, 15.62; N, 12.15. $C_{23}H_{18}Cl_2N_4O_2$. Calculated (%): C, 60.94; H, 4.00; Cl, 15.64; N, 12.36. MS, m/z (I_{rel} (%)): 453 [M]⁺ (1), 439 (72), 437 [M – Me – H]⁺ (100). IR (CHCl₃), v/cm^{-1} : 3400 (NH), 3020, 1712 (CO), 1652, 1628, 1560. ¹H NMR (CDCl₃), δ : 0.94 (s, 6 H, 2 Me); 2.21 (s, 2 H, CH₂); 4.00 (s, 1 H, H(9)); 7.17 (d, 2 H, o-H_{C₆H₄}, J = 8.0 Hz); 7.22 (d, 2 H, o-H_{C₆H₄}, J = 8.0 Hz); 7.50 (m, 4 H, m-H, 2 C₆H₄). ¹³C NMR (CDCl₃), δ : 28.60 (2 Me); 32.33 (C(8)); 40.11 (C(7)); 95.03 (C(9b)); 106.91 (C(9)); 129.26 (o-C_{C₆H₄}); 130.28 (m-C, 2 C₆H₄); 130.37 (o-C_{C₆H₄}); 130.72 (C(9a)); 134.56 (ipso-C_{C₆H₄}); 134.86 (p-C_{C₆H₄}); 135.02 (ipso-C_{C₆H₄}); 135.58 (p-C_{C₆H₄}); 154.81

(C(6a)); 148.80, 155.53, 156.59 (C(2), C(3a), C(5)). Assignment of the signals performed was based on the ${}^{1}H/{}^{13}C$ HMBC two-

dimensional NMR.

1-(4-Chlorophenyl)-8,8-dimethyl-6-phenyl-7,8-dihydro-1*H*pyrimido [4,5,6-de] quinazoline -2,5(3H,6H) - dione (6c) and 6-(4chlorophenyl)-8,8-dimethyl-1-phenyl-7,8-dihydro-1*H*-pyrimido-[4,5,6-de]quinazoline-2,5(3H,6H)-dione (6d) were synthesized similarly to compound 6a from urea 5c and 5d. After concentration, the residue was purified by column chromatography on SiO₂ (chloroform) to obtain a mixture of unseparable isomers **6c** and **6d** (the ratio 1:1 according to the ¹H NMR spectral data), the yields were 67 and 80% from 5c and 5d, respectively, m.p. 284-285 °C. Found (%): C, 66.17; H, 4.62; Cl, 8.45; N, 13.00. $C_{23}H_{19}ClN_4O_2$. Calculated (%): C, 65.95; H, 4.57; Cl, 8.46; N, 13.38. MS, m/z (I_{rel} (%)): 418 [M]⁺ (29), 403 [M – Me]⁺ (100), 148 (24). IR (CHCl₃), v/cm⁻¹: 3400 (NH), 3020–2920 (NH, CH), 1712 (CO), 1668, 1652, 1628, 1560. ¹H NMR (600 MHz, CDCl₃), δ , isomer **6c**/isomer **6d**: 0.94/0.94 (s, 6 H, 2 Me); 2.22/2.22 (s, 2 H, CH₂); 3.99/4.00 (s, 1 H, H(9)); 7.16–7.25/ 7.16—7.25 (m, 4 H, $o-H_{C_6H_4}$, $o-H_{Ph}$); 7.47—7.52/7.47—7.52 (m, 5 H, m-H_{C₆H₄}, m-H_{Ph}, p-H_{Ph}); a signal for the proton from NH is very broad and resonates in the region ~8.70 ¹H NMR $(600 \text{ MHz}, \text{DMSO-d}_6), \delta$, isomer **6c**/isomer **6d**: 0.87/0.87 (s, 6 H, 2 Me); 2.20/2.22 (s, 2 H, CH₂); 3.81/3.79 (s, 1 H, H(9)); 7.32/ 7.27 (d, 2 H, o-H_{Ph}, J = 7.8 Hz); 7.32/7.39 (d, 2 H, o-H_{C₆H₄}, J = 7.8 Hz); 7.49/7.44 (t, 1 H, p-H_{Ph}, J = 7.8 Hz); 7.55/7.53 (t, 2 H, m-H_{Ph}, J = 7.8 Hz); 7.57/7.59 (d, 2 H, m-H_{C₆H₄}, J = 7.8 Hz). ¹³C NMR (DMSO-d₆), δ , isomer **6c**/isomer **6d**: 28.23/28.23 (2 Me); 31.40/31.40 (C(8)); 39.41/39.30 (C(7)); 93.77/93.98 (C(9b)); 104.50/104.63 (C(9)); 127.88/128.84 $(o-C_{Ph})$; 128.54/128.02 $(p-C_{Ph})$; 129.16/129.21 $(m-C_{Ph})$; 129.43/ 129.31 $(m-C_{C_6H_4})$; 130.87/129.93 $(o-C_{C_6H_4})$; 130.87/130.87 $(C(9a)); 132.66/\tilde{1}33.26 (p-C_{C_6H_4}); 135.53/\tilde{1}3\tilde{5}.87 (ipso-C_{C_6H_4}),$ 136.96/136.61 (*ipso*-C_{Ph}); 154.34/154.19 (C(6a)); 148.96, 154.62, 154.70, 156.74, 156.91 (C(2), C(3a), C(5) from two isomers. ¹⁵N NMR based on the ¹H/¹⁵N HMBC two-dimensional NMR spectrum (correlation on the ortho-protons of the aryl groups, the CH₂ or CH protons, DMSO-d₆), δ, isomer 6c/isomer 6d: -250/-248 (N(1)); -205/-207 (N(6)). The ${}^{1}H/{}^{1}H$ COSY, ¹H/¹³C HMBC and HSQC, and ¹H/¹⁵N HMBC two-dimensional NMR spectra were used to assign signals in the ¹H and

¹³C NMR spectra and to determine whether they belong to compound **6c** or **6d**.

This work was financially supported by the Russian Academy of Sciences (Program for Basic Research of the Presidium of RAS "Development of Methods for Preparation of Chemical Compounds and Creation of New Materials").

References

- 1. Eur. Pat. Appl., EP 351058; Chem. Abstrs, 1990, 113, 40711r.
- 2. J. Cieplic, J. Pluta, O. Gubrynowicz, *Acta Pol. Pharm.*, 2003, **60**, 487.
- 3. R. Gupta, A. Jain, R. Joshi, M. Jain, *Bull. Korean Chem. Soc.*, 2011, **32**, 899.
- 4. Eur. Pat. Appl., EP 163599; Chem. Abstrs, 1986, 104, 18643911
- 5. Ger. Offen., DE 3601731; Chem. Abstrs, 1988, 109, 54786y.
- J. E. Gready, C. Mc Kinlay, M. G. Gebauer, Eur. J. Med. Chem., 2003, 38, 719.
- V. A. Dorokhov, M. F. Gordeev, A. V. Komkov, V. S. Bogdanov, Izv. Akad. Nauk SSSR, Ser. Khim., 1991, 159 [Bull. Acad. Sci. USSR, Div. Chem. Sci. (Engl. Transl.), 1991, 40, 142].
- 8. V. A. Dorokhov, M. F. Gordeev, A. V. Komkov, V. S. Bogdanov, *Izv. Akad. Nauk SSSR*, *Ser. Khim.*, 1991, 2593 [*Bull. Acad. Sci. USSR*, *Div. Chem. Sci.* (*Engl. Transl.*), 1991, 40, 2267].
- A. V. Komkov, A. M. Sakharov, V. S. Bogdanov, V. A. Dorokhov, *Izv. Akad. Nauk, Ser. Khim.*, 1995, 1324 [Russ. Chem. Bull. (Engl. Transl.), 1995, 44, 1278].
- V. Dorokhov, A. Komkov, S. Baranin, *ARKIVOC*, 2003, 14, 178, www.arkat-usa.org, volume 2003, 14.
- V. A. Voronkova, A. V. Komkov, V. A. Dorokhov, *Izv. Akad. Nauk, Ser. Khim.*, 2009, 347 [*Russ. Chem. Bull.*, *Int. Ed.*, 2009, 58, 351].
- V. A. Dorokhov, V. A. Voronkova, A. V. Komkov, S. V. Baranin, L. S. Vasil'ev, *Izv. Akad. Nauk, Ser. Khim.*, 2010, 1012 [Russ. Chem. Bull., Int. Ed., 2010, 59, 1035].
- 13. H. Wamhoff, W. Lamers, Synthesis, 1993, 111.
- V. A. Voronkova, A. V. Komkov, A. S. Shashkov, V. A. Dorokhov, *Izv. Akad. Nauk, Ser. Khim.*, 2011, 141 [Russ. Chem. Bull., Int. Ed., 2011, 60, 148].
- 15. I. Trummer, E. Ziegler, O. S. Wolfbeis, Synthesis, 1981, 225.
- V. A. Mironov, A. D. Fedorovich, A. A. Akhrem, *Usp. Khim.*, 1981, 50, 1272 [*Russ. Chem. Rev. (Engl. Transl.*), 1981, 50, 666].

Received June 29, 2011; in revised form September 28, 2011